Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 10.45 USD 1.46% Market Closed
Market Cap: $1B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

SPRY Price Targets Summary
ARS Pharmaceuticals Inc

Wall Street analysts forecast SPRY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SPRY is 29.41 USD with a low forecast of 12.12 USD and a high forecast of 40.95 USD.

SPRY Lowest Forecast
Wall Street Target
12.12 USD
16% Upside
SPRY Average Forecast
Wall Street Target
29.41 USD
181% Upside
SPRY Highest Forecast
Wall Street Target
40.95 USD
292% Upside
Lowest
Price Target
12.12 USD
16% Upside
Average
Price Target
29.41 USD
181% Upside
Highest
Price Target
40.95 USD
292% Upside
ARS Pharmaceuticals Inc Competitors:
Price Targets
APA
APA Corp (US)
-1% Downside
GOSS
Gossamer Bio Inc
266% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
26% Upside
APA
APA Corp (US)
-1% Downside
GOSS
Gossamer Bio Inc
266% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
26% Upside

Revenue
Forecast

N/A
Past Growth
53% / Year
Estimated Growth
Estimates Accuracy
N/A
Average
N/A
Past Growth
53% / Year
Estimated Growth
Estimates Accuracy
N/A
Average

The compound annual growth rate of ARS Pharmaceuticals Inc's revenue for the next 4 years is 53%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
49% / Year
Estimated Growth
Estimates Accuracy
-70%
Average Miss
N/A
Past Growth
49% / Year
Estimated Growth
Estimates Accuracy
-70%
Average Miss

The compound annual growth rate of ARS Pharmaceuticals Inc's net income for the next 4 years is 49%.

What are analyst estimates?

See Also

Summary
SPRY intrinsic value, competitors valuation, and company profile.
DCF Valuation
SPRY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SPRY stock valuation using valuation multiples.
Wall Street Estimates
SPRY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SPRY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SPRY's stock price target?
Price Target
29.41 USD

According to Wall Street analysts, the average 1-year price target for SPRY is 29.41 USD with a low forecast of 12.12 USD and a high forecast of 40.95 USD.

What is ARS Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
53%

The compound annual growth rate of ARS Pharmaceuticals Inc's revenue for the next 4 years is 53%.

What is ARS Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
49%

The compound annual growth rate of ARS Pharmaceuticals Inc's net income for the next 4 years is 49%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 314,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.